Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
NCT04177810Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2020
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plerixafor and cemiplimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Objective Response Rate Using Immune RECIST Criteria at 10 months. Started Nov 2020; status: completed.
02
Drugs
plerixaforcemiplimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04177810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177810.